Skip to search formSkip to main contentSkip to account menu

BMS 232632

Known as: 232632, BMS, BMS-232632, BMS232632 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2002
Highly Cited
2002
ABSTRACT The in vitro inhibition of wild-type human immunodeficiency virus (HIV) by combinations of lopinavir and six other… 
2001
2001
BMS-232632 is a potent human immunodeficiency type 1 (HIV-1) protease inhibitor with a half-life that allows for once-daily… 
2001
2001
BMS-232632, an azapeptide HIV protease inhibitor, is in development by Bristol-Myers Squibb (BMS), under license from Novartis… 
Highly Cited
2000
Highly Cited
2000
ABSTRACT BMS-232632 is an azapeptide human immunodeficiency virus (HIV) type 1 (HIV-1) protease inhibitor that displays potent… 
2000
2000
At the 5th International Congress on Drug Therapy in HIV Infection, held in Glasgow, Scotland, October 22-26, 2000, the…